Safety narratives are the clearest case in regulated writing where volume and judgement pull in opposite directions. A study can need hundreds of them. Each one has to be complete, consistent with the case record, and readable. And they are usually written late, under deadline, by whoever is free.
That makes them a good fit for software, provided you hold one line firmly. This is what to look for.
What a narrative is, and what it is not
ICH E3 asks for narratives for deaths, other serious adverse events and certain other significant adverse events in a clinical study report. Each one tells the story of a single case: who the patient was, what they were taking, what happened, when, what was done, and how it ended.
That is two different kinds of content. The description is a structured account of facts already in the case record. The assessment is causality and clinical reasoning, which a qualified person decides and signs. Good software drafts the first and leaves the second alone.
The failure to design against
The risk is not bad grammar. It is a narrative that says something the case record does not support. A date that does not match. A medication that was never recorded. An outcome stated more firmly than the data allows.
Those are not style problems. A narrative that disagrees with its own case is a data integrity issue, and at the volumes involved, nobody catches it by sampling. So the requirement is simple to state: every statement in the narrative must trace to the field it came from, and a reviewer must be able to check it without leaving the page.
Review at volume, honestly
This is where narrative tools either work or quietly turn into a rubber stamp.
If one reviewer has to approve several hundred narratives a day, review is not really happening, and everyone involved knows it. Claiming human oversight that cannot physically take place is worse than admitting the automation, because it misleads the people relying on the control.
Two things make review real. Source traceability, so checking a statement takes a glance rather than an investigation. And sensible tiering, with full review for serious, fatal and unexpected cases and lighter review for the routine tail, written down and justified rather than drifting into place. Our piece on why human review can't be a footnote explains why the rejection path matters as much as the review itself.
Consistency across the whole set
An underrated benefit. Each narrative can be correct on its own while the set is not. The same event described three different ways. The same drug coded twice. Terms drifting as different writers joined the work.
A reviewer reading one narrative at a time cannot see this. Software checking the whole set against source can, and that kind of inconsistency is exactly what reads as an uncontrolled process during an inspection.
What to ask before you buy
- Does every statement link back to the case record field it came from?
- Are causality and the company comment explicitly excluded from drafting?
- Can you tier review by case seriousness, and is that tiering recorded?
- Does it check consistency across the whole set, not just within one narrative?
- What happens to your reporting deadline if the tool is down? The manual path has to work.
Where to start
The routine, non-serious cases first. They are the highest volume and the lowest judgement, and they are where the backlog builds. Keep serious, fatal and unexpected cases on your existing path until you trust the approach.
See TraceDraft for safety narratives and our safety narrative service, or talk to us about running it on your own cases.
Where to go next
Explore GxP Copilot for AI-native validation, TraceDraft for source-traceable clinical documentation, or book a demo to see either on your own data.